标题
The application of BH3 mimetics in myeloid leukemias
作者
关键词
-
出版物
Cell Death & Disease
Volume 12, Issue 2, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-26
DOI
10.1038/s41419-021-03500-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Targeting MCL-1 in hematologic malignancies: Rationale and progress
- (2020) AndrewH. Wei et al. BLOOD REVIEWS
- AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia
- (2020) Xue Yi et al. CLINICAL CANCER RESEARCH
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML
- (2020) Myriam Hormi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
- (2019) Claudia Iavarone et al. MOLECULAR CANCER THERAPEUTICS
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia
- (2019) Jun Ma et al. CLINICAL CANCER RESEARCH
- BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
- (2019) Jing-dong Zhou et al. Diagnostic Pathology
- Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity
- (2019) Zoltan Szlávik et al. JOURNAL OF MEDICINAL CHEMISTRY
- TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1
- (2019) Bing Z Carter et al. BLOOD
- Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)
- (2019) Wittawat Chantkran et al. BLOOD
- AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.
- (2019) Justin Cidado et al. CLINICAL CANCER RESEARCH
- Mitochondria as multifaceted regulators of cell death
- (2019) Florian J. Bock et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
- (2018) Yichao Wan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Acute myeloid leukaemia
- (2018) Nicholas J Short et al. LANCET
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
- (2018) Ryan S. Soderquist et al. Nature Communications
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
- (2017) Joel D. Leverson et al. Cancer Discovery
- iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
- (2016) Jeremy Ryan et al. BIOLOGICAL CHEMISTRY
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
- (2016) X. Niu et al. CLINICAL CANCER RESEARCH
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Mutations in AML: prognostic and therapeutic implications
- (2016) C. D. DiNardo et al. Hematology-American Society of Hematology Education Program
- Acute Myeloid Leukemia: A Concise Review
- (2016) Jennifer Saultz et al. Journal of Clinical Medicine
- Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
- (2016) Valentina Cappello et al. Scientific Reports
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- (2015) A. Baker et al. CANCER RESEARCH
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
- (2015) Avi Ashkenazi JOURNAL OF CLINICAL INVESTIGATION
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
- (2015) G S Choudhary et al. Cell Death & Disease
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
- (2015) Jo Ishizawa et al. PLoS One
- The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
- (2015) Tun Kiat Ko et al. Oncotarget
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells
- (2014) Mariarita Perri et al. EXPERIMENTAL CELL RESEARCH
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
- (2014) J M Bogenberger et al. LEUKEMIA
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
- (2014) James M. Bogenberger et al. LEUKEMIA & LYMPHOMA
- Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage
- (2014) Chengzhi Xie et al. Molecular Oncology
- Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells
- (2013) Jing Yang et al. APOPTOSIS
- miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein
- (2013) Yajuan Li et al. EXPERIMENTAL CELL RESEARCH
- Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
- (2013) R. L. Thomas et al. GENES & DEVELOPMENT
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- BH3 profiling in whole cells by fluorimeter or FACS
- (2013) Jeremy Ryan et al. METHODS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
- (2012) Twee Tsao et al. ANNALS OF HEMATOLOGY
- How I treat CML blast crisis
- (2012) R. Hehlmann BLOOD
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
- (2012) M. Rahmani et al. BLOOD
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38− population to imatinib
- (2012) Kelly Airiau et al. EXPERIMENTAL HEMATOLOGY
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors
- (2011) D H Mak et al. LEUKEMIA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Molecular biology of Bax and Bak activation and action
- (2010) Dana Westphal et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia
- (2010) Zhifu Xiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Resistance to Imatinib: Mutations and Beyond
- (2010) Paul La Rosée et al. SEMINARS IN HEMATOLOGY
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
- (2009) G. Yoshimoto et al. BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
- (2008) G Kroemer et al. CELL DEATH AND DIFFERENTIATION
- Living with death: the evolution of the mitochondrial pathway of apoptosis in animals
- (2008) A Oberst et al. CELL DEATH AND DIFFERENTIATION
- Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
- (2008) W Zhang et al. LEUKEMIA
- BCL-2 family antagonists for cancer therapy
- (2008) Guillaume Lessene et al. NATURE REVIEWS DRUG DISCOVERY
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now